CMPSN Stock Chart & Stats
$211.00
-$31.00(-12.81%)
―
--
Day’s Range― - ―
52-Week Range$69.69 - $260.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$26.56B
Enterprise Value$307.29
Total Cash (Recent Filing)$466.01M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Jul 30, 2026EPS Estimate
-6.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$437.72Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Pivotal Clinical DatasetLarge, durable Phase III data (nearly 600 in Part B, >1,000 across program) provide a durable clinical differentiation. Sustained single- and retreatment responses and tolerability strengthen label claims, support payer conversations and lower execution risk for commercialization over the next 2–6 months.
Rolling NDA With Priority VoucherA rolling NDA and the Commissioner's National Priority Voucher materially shorten regulatory timelines if used, reducing time-to-market uncertainty. This structural regulatory advantage compresses the period of execution risk and supports earlier revenue potential and planning stability for launch activities.
Commercial Readiness And RunwayPost-financing runway into 2028 plus experienced commercial hires materially improves probability of an organized launch. Availability of capital and a built-out commercial organization reduces short-term financing pressure and increases the odds of effective site onboarding and payer engagement during initial market entry.
Bears Say
Persistent Pre-revenue Losses And Cash BurnThe company remains pre-revenue with deep, recurrent operating and free cash flow deficits, creating structural dependence on external financing until commercial revenues materialize. Persistent cash burn elevates dilution and execution risk and constrains flexibility during the critical launch and reimbursement periods.
Reimbursement And CPT Valuation UncertaintyCategory III tracking codes provide limited, temporary reimbursement certainty; progressing to Category I and achieving durable RVU valuation requires RUC/AMA work, real-world evidence and committee timing. This structural reimbursement gap can constrain physician economics and slow uptake even after approval.
Regulatory Sequencing And REMS/DEA UncertaintySequencing between FDA advisory processes, DEA rescheduling and REMS design could add months or operational complexity to launch. Open REMS/staffing requirements and DEA timing are structural execution risks that affect site readiness, training needs and early patient access even with an accelerated review mechanism.
CMPSN FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $69.69 and its highest was $260.00 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $26.56B.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is Jul 30, 2026 which is in 4 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on May 13, 2026. The company reported $12.431 earnings per share for the quarter, beating the consensus estimate of -$7.686 by $20.118.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -6.76.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,949,330 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of $12.431 in its last earnings report, beating expectations of -$7.686. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in MX:CMPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$437.72 (― Downside)
$437.72 (― Downside)
Blogger Sentiment
Bullish
MX:CMPSN Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
153.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
66.62%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPSN Stock 12 Month Forecast
Average Price Target
$437.72